(a) While homologs were identified for 99% of the human glycosylation-associated transcripts, only 53% had detectable expression. Glycosylation gene classes enriched in expressed genes (denoted with **) include hyaluronoglucosaminidases, sugar-nucleotide synthesis, mannosyltransferases, and lysozomal enzymes. Significantly depleted classes in expressed genes (denoted with *) include the sulfotransferases, fucosyltransferases, and GalNAc transferases. (b) A selection of CHO N-linked glycosylation pathways are detailed to demonstrate the effects of CHO glycosylation gene expression on the possible glycoforms. (i) A difference between human and CHO glycosylation is seen in the lack of expression of MGAT3, which is responsible for the bisecting β(1,4) GlcNAc that occurs on ~10% of human antibodies. (ii) The only N-glycan-modifying fucosyltransferase expressed in CHO-K1 is FUT8, which adds fucose to the core glycan by an α(1,6) linkage. (iii) Sialylation of a terminal galactose can occur via α(2,3) or α(2,6) linkages in human. However, CHO ST6Gal genes are not expressed, so CHO glycans primarily have α(2,3) linkages. (iv)The two most abundant sialic acids are Neu5Ac and Neu5Gc. Neu5Gc is immunogenic in humans. Thus, the lack of CMAH expression in CHO minimizes this response by limiting the conversion of Neu5Ac to Neu5Gc. Pathways are adapted loosely from 55. Abbreviations are defined in Supplementary Table 18.